Subscribe
shutterstock_733304062_casimiro_pt
Casimiro PT / Shutterstock.com
26 July 2019AmericasSarah Morgan

Bio-Rad wins injunction against 10X Genomics

Bio-Rad, a developer of clinical diagnostic products, secured a permanent injunction against a competitor earlier this week in a long-running dispute.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

More on this story

Medtech
Fed Circ. agrees Bio-Rad infringed 10x patents
4 May 2021   The US Court of Appeals for the Federal Circuit has affirmed a US International Trade Commission (ITC) decision that ruled Bio-Rad Laboratories had infringed three 10x Genomics patents.
Big Pharma
Federal Circuit upholds another ITC decision in 10X vs Bio-Rad
3 June 2021   The US Court of Appeals for the Federal Circuit has upheld a decision from the US International Trade Commission that found 10X Genomics infringed on two Bio-Rad Laboratories gene sequencing patents.
Big Pharma
Bio-Rad asks for review of DNA patent ruling
17 June 2021   Bio-Rad has asked the US Court of Appeals for the Federal Circuit to review its prior decisions that affirmed Bio-Rad had infringed three 10X Genomics patents.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers